Aaron Cox - Horizon Pharma Exec CFO
Insider
Aaron Cox is Exec CFO of Horizon Pharma PLC
| Age | 40 |
| Phone | 353 1 772 2100 |
| Web | https://www.horizontherapeutics.com |
Horizon Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Horizon Pharma PLC currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Horizon Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Quigley | Gilead Sciences | N/A | |
| Stephen Mayo | Merck Company | 59 | |
| Patrice Bula | Novartis AG ADR | 65 | |
| Paul Hudson | Sanofi ADR | 58 | |
| Shobie Ramakrishnan | GlaxoSmithKline PLC ADR | 54 | |
| Azita Gerhardt | AbbVie Inc | 57 | |
| Jennifer Mauer | Merck Company | N/A | |
| Martin MIBS | Eli Lilly and | 61 | |
| Jonathan Symonds | GlaxoSmithKline PLC ADR | 62 | |
| Risa LavizzoMourey | Merck Company | 66 | |
| Jitendra Tyagi | Bristol Myers Squibb | N/A | |
| Claudia Bockstiegel | Roche Holding Ltd | 59 | |
| Jannie Oosthuizen | Merck Company | 53 | |
| Michael Klobuchar | Merck Company | 45 | |
| Pascale Schmidt | Roche Holding Ltd | 50 | |
| D Davis | Johnson Johnson | 69 | |
| Kimberly Johnson | Eli Lilly and | 48 | |
| BCH BM | Bristol Myers Squibb | 57 | |
| Josephine Fubara | Sanofi ADR | N/A | |
| Dirk Brinckman | Johnson Johnson | N/A | |
| Victor Bulto | Novartis AG ADR | 47 | |
Management Performance
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 |
Horizon Pharma PLC Leadership Team
Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jane Gonnerman, Office Staff | ||
| Sean JD, Exec Counsel | ||
| Timothy Walbert, Chairman, CEO and Pres | ||
| Tina Ventura, Senior Vice President Investor Relations | ||
| Patrick McIlvenny, VP Officer | ||
| Paul Hoelscher, CFO and Executive VP of Fin. | ||
| FACP FACP, Ex Officer | ||
| Andy Pasternak, Ex Officer | ||
| Aaron Cox, Exec CFO | ||
| Geoffrey Curtis, Senior Vice President - Corporate Communications |
Horizon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X |
Pair Trading with Horizon Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |